PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial
May 06, 2021 03:30 ET | Peptomyc S.L.
BARCELONA, Spain, May 06, 2021 (GLOBE NEWSWIRE) -- Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research...
Peptomyc’s Omomyc-based therapy, OMO-103, has obtained approval for first-in-human phase I/II trial to assess the efficacy and safety of a novel Myc inhibitor
March 18, 2021 06:52 ET | Peptomyc S.L.
BARCELONA, Spain, March 18, 2021 (GLOBE NEWSWIRE) -- Co-founded back in 2014 by VHIO’s Laura Soucek, CEO of the enterprise, and Marie-Eve Beaulieu, Chief Scientific Officer (CSO) of the company,...
Peptomyc Board of Directors appoints Giacomo Di Nepi as Chairman of the Board
January 06, 2021 18:00 ET | Peptomyc S.L.
BARCELONA, Spain, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Peptomyc S.L., a biotech company specialized in the development of protein and peptide therapeutics targeting the Myc oncoprotein for cancer...